Company profile
Lucid Diagnostics Inc.
NASDAQ: LUCD · Healthcare · Medical - Devices
#716 of 1,422 Healthcare companies by revenue54th-percentile growth
EA Score
35DFH 25DQ 37GM 56SS 47
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, market scale · ↓ return on equity, listing tenure
Methodology →Revenue TTM
$5.4M
Rev growth YoY (TTM)
+24.9%
Net income (FY)
-$58.0M
Employees
82
as of 2026-08-18
Market cap
$184.4M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.7M$4.7M2025
Net income-$58.0M-$58.0M2025
Operating income-$49.6M-$49.6M2025
Total assets$40.4M$40.4M2025
Liabilities$29.5M$29.5M2025
Equity$10.9M$10.9M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lucid Diagnostics Inc.’s revenue?
Lucid Diagnostics Inc. booked $4.7M in FY2025 revenue, growing 8.3% year over year — about the middle of the pack among Healthcare companies we track, at a -1232.7% net margin.
Peers · Healthcare
Procyon Corporation——InMed Pharmaceuticals Inc.45DPicard Medical, Inc.25DPrime Medicine, Inc.37DHealthy Extracts Inc.69BOcugen, Inc.44DNeighbors
New York →Key facts
CEOLishan Aklog
SectorHealthcare
IndustryMedical - Devices
HeadquartersNew York City, NY
ExchangeNASDAQ: LUCD
Employees82
IPO date2021-10-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.